WORLD TRADE

ORGANIZATION

WT/L/5402 September 2003

(03-4582)

IMPLEMENTATION OF PARAGRAPH 6 OF THE DOHA DECLARATION ON THE TRIPS AGREEMENT AND PUBLIC HEALTH

Decision of 30 August 2003*

The General Council,

Having regard to paragraphs 1, 3 and 4 of Article IX of the Marrakesh Agreement Establishing the World Trade Organization ("the WTO Agreement");

Conducting the functions of the Ministerial Conference in the interval between meetings pursuant to paragraph 2 of Article IV of the WTO Agreement;

Noting the Declaration on the TRIPS Agreement and Public Health (WT/MIN(01)/DEC/2) (the "Declaration") and, in particular, the instruction of the Ministerial Conference to the Council for o fileRdPsr36(nWn2(d3))Tpx6(E)Q)T(6Wfcths)D8c24c3ti39etm)Ifffd in 6(x)4c4(tictusapollu2(r3)) x8.24e-pr3Blyins(ous).-2.73in)609 pharmaceutical sector could face in making effective use of compulsory licensing under the TRIPS Agreement and to report to the General Council before the end of 2002;

(b) "eligible importing Member" means any least-developed country Member, and any other Member that has made a notification² to the Council for TRIPS of its intention to use the system as an importer, it being understood that a Member may notify at any

insufficient for this purpose, the matter may be reviewed in the Council for TRIPS at the request of that Member.

- 6. With a view to harnessing economies of scale for the purposes of enhancing purchasing power for, and facilitating the local production of, pharmaceutical products:
 - where a developing or least-developed country WTO Member is a party to a regional trade agreement within the meaning of Article XXIV of the GATT 1994 and the Decision of 28 November 1979 on Differential and More Favourable Treatment Reciprocity and Fuller Participation of Developing Countries (L/4903), at least half of the current membership of which is made up of countries presently on the United Nations list of least-developed countries, the obligation of that Member under Article 31(f) of the TRIPS Agreement shall be waived to the extent necessary to thatMe(m)18.8(b)1.8(er

 9D-0.062(ii)-10.8 63d,n (r)T57TD0.001(as)10.5(t-)19.6(deprablimin(ques)1072(t)-2.8(i)8.1on. (I)1982(t)-2.8 (is(unu)12.9het)89(stoou)12.9dfinht(i)8.1seill preo

(tii) i (isreco(g)1371no-2.8(ze)14.9(ed tha)1192(t)-2t)-10.8 the deve.1(lv)32.7pmInt

part of the negotiations referred to in paragraph 45 of the Doha Ministerial Declaration (WT/MIN(01)/DEC/1).

ANNEX

Assessment of Manufacturing Capacities in the Pharmaceutical Sector

Least-developed country Members are deemed to have insufficient or no manufacturing capacities in the pharmaceutical sector.

For other eligible importing Members insufficient or no manufacturing capacities for the product(s) in question may be established in either of the following ways:

(i) the Member in question has established that it has no manufacturing capacity in the pharmaceutical sector;

OR

(ii) where the Member has some manufacturing capacity in this sector, it has examined this capacity and found that, excluding any capacity owned or controlled by the patent owner, it is currently insufficient fo